Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Liu, Gengqi; Lovell, Jonathan F.; Zhang, Lei; Zhang, Yumiao

doi:10.3390/ijms21176380

Cited by 43 publications

(22 citation statements)

References 280 publications

(299 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…stimuli. This selective targeting improves the therapeutic effects, lowers toxicity, and reduces the incidence of side effects ( Liu et al, 2020 ).…”

Section: Strategies For the Manipulation Of Macrophages By Nanomaterialsmentioning

confidence: 99%

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Cai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, progressive, and systemic inflammatory autoimmune disease, characterized by synovial inflammation, synovial lining hyperplasia and inflammatory cell infiltration, autoantibody production, and cartilage/bone destruction. Macrophages are crucial effector cells in the pathological process of RA, which can interact with T, B, and fibroblast-like synovial cells to produce large amounts of cytokines, chemokines, digestive enzymes, prostaglandins, and reactive oxygen species to accelerate bone destruction. Therefore, the use of nanomaterials to target macrophages has far-reaching therapeutic implications for RA. A number of limitations exist in the current clinical therapy for patients with RA, including severe side effects and poor selectivity, as well as the need for frequent administration of therapeutic agents and high doses of medication. These challenges have encouraged the development of targeting drug delivery systems and their application in the treatment of RA. Recently, obvious therapeutic effects on RA were observed following the use of various types of nanomaterials to manipulate macrophages through intravenous injection (active or passive targeting), oral administration, percutaneous absorption, intraperitoneal injection, and intra-articular injection, which offers several advantages, such as high-precision targeting of the macrophages and synovial tissue of the joint. In this review, the mechanisms involved in the manipulation of macrophages by nanomaterials are analyzed, and the prospect of clinical application is also discussed. The objective of this article was to provide a reference for the ongoing research concerning the treatment of RA based on the targeting of macrophages.

show abstract

“…stimuli. This selective targeting improves the therapeutic effects, lowers toxicity, and reduces the incidence of side effects ( Liu et al, 2020 ).…”

Section: Strategies For the Manipulation Of Macrophages By Nanomaterialsmentioning

confidence: 99%

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Cai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…“Smart” nanoparticles have also been engineered to respond to exogenous and endogenous stimuli and acting as sensing devices. The application of stimuli triggers the alternation or the disruption of NPs resulting in active molecules release both on demand and in a targeted manner [ 128 ]. Various endogenous stimuli have been exploited from the microenvironment features associated with pathological conditions.…”

Section: Nanotechnologies As Sensor Devicesmentioning

confidence: 99%

Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases

Talamini

Matsuura

Cola

et al. 2021

Cells

View full text Add to dashboard Cite

The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.

show abstract

“…Additionally, when further formulating these nanoparticles it is important to consider that pH responsive systems may be limited by low sensitivity. It can be combined with other types of endogenous stimuli e.g., redox, enzymes to improve selectivity of drug release in diseased tissue [64]. Applying this combined approach to other types of ovarian (e.g., endometriod, A2780) and other types of cancer e.g., breast cancer would also be of interest.…”

Section: Synergy Of Drug Combination With the Paclitaxel Prodrugmentioning

confidence: 99%

Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation

Levit

Gade

Roper

et al. 2020

IJMS

View full text Add to dashboard Cite

The efficacy of paclitaxel (PTX) is limited due to its poor solubility, poor bioavailability, and acquired drug resistance mechanisms. Designing paclitaxel prodrugs can improve its anticancer activity and enable formulation of nanoparticles. Overall, the aim of this work is to improve the potency of paclitaxel with prodrug synthesis, nanoparticle formation, and synergistic formulation with lapatinib. Specifically, we improve potency of paclitaxel by conjugating it to α-tocopherol (vitamin E) to produce a hydrophobic prodrug (Pro); this increase in potency is indicated by the 8-fold decrease in half maximal inhibitory concentration (IC50) concentration in ovarian cancer cell line, OVCA-432, used as a model system. The efficacy of the paclitaxel prodrug was further enhanced by encapsulation into pH-labile nanoparticles using Flash NanoPrecipitation (FNP), a rapid, polymer directed self-assembly method. There was an 1100-fold decrease in IC50 concentration upon formulating the prodrug into nanoparticles. Notably, the prodrug formulations were 5-fold more potent than paclitaxel nanoparticles. Finally, the cytotoxic effects were further enhanced by co-encapsulating the prodrug with lapatinib (LAP). Formulating the drug combination resulted in synergistic interactions as indicated by the combination index (CI) of 0.51. Overall, these results demonstrate this prodrug combined with nanoparticle formulation and combination therapy is a promising approach for enhancing paclitaxel potency.

show abstract

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Cited by 43 publications

References 280 publications

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases

Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation

Contact Info

Product

Resources

About